We are pleased to congratulate BD Capital on the sale of Symprove to Metagenics. OC&C supported BD Capital with sell-side commercial due diligence in preparation for the transaction.
Symprove is a fast-growing gut health brand offering a unique water-based probiotic supplement backed by independent clinical research. Since BD Capital’s investment in 2020, Symprove has expanded significantly through broadening its customer base, strengthening its digital proposition and accelerating growth in the UK and internationally. The transaction marks a significant milestone in the brand’s development and will support further international scale-up under Metagenics’ ownership.
Metagenics is a US-based, science-backed provider of nutritional supplements, active in over 40 countries. The acquisition of Symprove adds a highly complementary product and brand to its growing global portfolio and strengthens its position in the fast-evolving consumer health space.
We are a leading global strategy consultancy with deep experience across consumer health. We bring strategic clarity to brands, retailers and investors. We support our clients across the full deal cycle, adding value at every stage by answering the strategic questions that arise as they navigate shifting consumer preferences, evolving channel dynamics, and international growth opportunities.
We’re a leading global strategy consultancy, working with both major global corporations and local champions. In private equity, we have commercially advised on more than 500 successful transactions over the last 5 years, encompassing sell-side and buy-side roles.
How we can help:
For more details on our experience in this space, get in touch with our experts or email [email protected].
Partner
Partner
Um Zugang zum vollständigen Bericht zu erhalten, füllen Sie bitte das nachstehende Formular aus.
„*“ zeigt erforderliche Felder an